-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Joins Forces with China Pharmaceutical University to Advance Innovative Drug Development
Category:
Time：2021-06-29
On June 25, Shijiazhuang Sihua Pharmaceutical Co., Ltd. and China Pharmaceutical University held a grand ceremony to sign a strategic cooperation agreement and unveil the joint laboratory. This marks another successful step in the company’s development of a university-enterprise R&D and innovation collaboration platform, which will strongly propel the company’s innovative drug research and development and the industrialization of high-end pharmaceuticals to new heights.
Lu Tao, Vice President of China Pharmaceutical University, Dai Baojin, Deputy Director of Shijiazhuang High-tech Zone, and Qu Jiguang, Chairman of the Board of Directors of Shisi Pharmaceutical Group, jointly unveiled the joint laboratory.
Shijiazhuang No.4 Pharmaceutical Co., Ltd. enjoys a long-standing, friendly cooperative relationship with China Pharmaceutical University. As a key national “Double First-Class” university in China that excels in both teaching and research in the field of pharmacy, China Pharmaceutical University has achieved remarkable and fruitful results in talent cultivation and pharmaceutical R&D. The signing of a strategic cooperation agreement and the establishment of a joint laboratory with China Pharmaceutical University mark another solid step forward in our collaboration between the university and the company.
This strategic cooperation between Shijiazhuang No.4 Pharmaceutical and China Pharmaceutical University is anchored in project development, leveraging the complementary strengths of both parties in terms of project resources and talent. It focuses on the company’s industrial development strategy, targeting innovative needs such as novel compounds and innovative small-molecule targeted drugs. Through the establishment of a joint laboratory, the collaboration will encompass a range of practical initiatives, including technical guidance for generic drug development, evaluation of innovative drug pipeline projects, and joint R&D of breakthrough therapies. This partnership aims to cultivate a high-caliber talent pool for innovation, significantly enhance the company’s overall efficiency and capability in innovative drug R&D, and prioritize the transfer, licensing, and commercialization of innovative results within the company itself. The goal is to have more than five first-in-class new drugs enter clinical trials within 2 to 3 years and to achieve large-scale production of even more first-in-class new drugs within 3 to 5 years. This initiative will accelerate the transformation of the company’s supply-side structure, facilitating its shift from a “single-industry focus” to a “multi-industry balanced approach,” and thereby driving and boosting the high-quality development of our province’s biopharmaceutical industry.
Su Xuejun, Chairman of Shiyao Group, and Lu Tao, Vice President of China Pharmaceutical University, signed the strategic cooperation agreement on behalf of their respective sides.
In recent years, Shijiazhuang Fourth Pharmaceutical has been driven by innovation, establishing high-level innovation platforms such as a national enterprise technology center, a national-local joint engineering laboratory, an academician workstation, and a postdoctoral research workstation. As a result, its innovation capabilities and levels have rapidly improved, giving rise to a new industrial structure characterized by synergistic development of liquid dosage forms, specialty APIs, oral formulations and specialized preparations, and biopharmaceuticals. Currently, the company has over 200 new products in various stages of research and development, with several first-in-class innovative drug studies accelerating their progress. Each year, the company obtains approval for more than 20 new product varieties, and its product dosage forms are becoming increasingly diverse. The industrial structure is undergoing rapid transformation, endowing the company with multiple competitive advantages—including advanced manufacturing, R&D of new technologies, new products, and new materials, leading-edge applications, and industrialization—thus making it a new benchmark for product innovation in the industry.
The event was chaired by Wu Hengyao, President of Shijiazhuang Fourth Pharmaceutical Group. Leaders and experts from China Pharmaceutical University, as well as officials from relevant departments of the Shijiazhuang High-Tech Zone, attended the ceremony.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code